Mitofusin-2 gene polymorphisms and metabolic dysfunction associated fatty liver disease: a case-control study in a Chinese population

Abstract

Objectives

Mitofusion-2 (Mfn2) may have a role in mitochondrial oxidative stress and insulin resistance that can promote the development of metabolic dysfunction associated fatty liver disease (MAFLD). This retrospective and case control study aimed to explore the relationships between common Mfn2 single nucleotide polymorphisms (SNPs) and MAFLD in a northern Han Chinese population.

Methods

Six Mfn2 SNPs (rs2336384, rs873458, rs873457, rs4846085, rs2878677, and rs2236057) were genotyped using the ligase detection reaction in 466 MAFLD patients and 423 healthy controls. Genotype and allele frequencies were calculated, along with haplotype analysis and pairwise linkage disequilibrium.

Results

The genotype distribution of rs2336384, rs2878677, and rs2236057 among the MAFLD patients showed a significantly different pattern from that of healthy controls. The data showed that an increased risk of MAFLD was significantly correlated with patients carrying the GG genotype of rs2336384, CC genotype of rs873457, TT genotype of rs4846085, TT genotype of rs2878677, and the AA genotype of rs2236057. Moreover, The GGCTTA haplotype was found to be adversely linked with MAFLD by haplotype analysis.

Conclusion

The current findings suggest a strong link between certain Mfn2 gene polymorphisms and MAFLD.

Keywords

Metabolic dysfunction associated fatty liver disease mitofusion-2 polymorphism haplotype genetic association gene expression intron

Introduction

Previously known as non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction associated fatty liver disease (MAFLD) is a chronic condition characterized by hepatic fat accumulation combined with underlying metabolic dysregulation.¹ It is the most common chronic liver disease worldwide.² A quarter of the adult population worldwide is affected by MAFLD, resulting in a significant clinical and financial burden.^3,4 The high prevalence of this disease may be at least partly caused by increasingly sedentary lifestyles with little physical exercise, overnutrition, and unhealthy diets.⁵ However, there is evidence suggesting that MAFLD is a multifactorial disease influenced not only by environmental determinants, but also by genetic predisposition, which promotes geographical demarcation of the disorder.⁴ Thus, there is a need to more precisely define patient phenotypes and genetic backgrounds to develop effective treatment strategies.^6,7 Many studies have aimed to identify the specific susceptibility loci for fatty liver disease. Patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) have been associated with MAFLD.⁸ There are some indications that Mitofusion-2 (MFN2) is associated with MAFLD, however, information concerning the connection between Mfn2 gene polymorphisms and MAFLD is limited.

The Mfn2 gene maps to chromosome 1p36.22 and encodes a protein with GTPase activity in the mitochondrial outer membrane. Mitochondria produce most of the ATP required for metabolism, and the aerobic nature of ATP generation also produces reactive oxygen species (ROS). Thus, mitochondrial dysfunction may result in damage to liver cells.⁹ The Mfn2 gene plays roles in mitochondrial fusion, division, energy generation, and thereby cell metabolism. Therefore, aberrant expression of Mfn2 may promote oxidative and endoplasmic reticulum (ER) stress, resulting in liver cell damage.¹⁰ Several studies have linked Mfn2 to insulin resistance (IR),¹¹ mitophagy,¹² and the proliferation of vascular smooth muscle cells,^13,14 all of which are associated with metabolic disorders. We speculated that Mfn2 may have an impact on MAFLD via the pathological processes outlined above. Previous studies have examined the associations between Mfn2 gene polymorphisms and metabolic syndrome diseases, such as type 2 diabetes¹⁵ and essential hypertension.^16–18 However, there have been few reported indications of any correlation between Mfn2 single nucleotide polymorphisms (SNPs) and MAFLD. In this study, we aimed to address these deficiencies by performing an in-depth investigation of the relationship between Mfn2 polymorphisms and MAFLD in a northern Han Chinese population.

Materials and methods

Subjects

Subjects presenting at the physical examination center of Third Hospital of Hebei Medical University, Shijiazhuang, China between October and December 2020 were enrolled in the study. All individuals were of northern Han descent and there was no evidence of intermarriage within the cohort. The new diagnostic criteria for MAFLD were applied, with hepatic steatosis being identified by two clinical ultrasound experts.² All subjects were over 18 years of age. Subjects who had undergone liver surgery, had forms of liver disease other than MAFLD, or had any other disease likely to cause fatty liver were excluded. The retrospective study was approved and supervised by the Ethics Committee of the Third Hospital of Hebei Medical University (approval number: 2019-005-1; date: 2019-4-23) and complied with the Principles of the Helsinki Declaration. All participants provided written informed consent for genetic testing. We have de-identified all patient details in this report. The reporting of this study conforms to STROBE guidelines.¹⁹

Baseline information, including age, sex, medical history, and family history of MAFLD, was collected by questionnaire. Patient height and body weight were measured using an electronic instrument (Omron, Shenzhen, China) and the body mass index (BMI) was calculated according to the formula: body weight (kg)/height² (m²). Electronic sphygmomanometers were used to measure blood pressure (Citizen, Jiangmen, Japan). Venous blood was collected in the morning after fasting for 8 to 12 hours. An automated blood cell analyzer was used to produce a white blood cell (WBC) count and an automated biochemical analyzer was used to generate liver biochemical indices (Beckman Coulter, Brea, CA, USA).

SNP identification and genotyping

Six Mfn2 SNPs (rs2336384, rs873458, rs873457, rs4846085, rs2878677, and rs2236057) were selected from previous reports of variants associated with metabolic dysfunction.^15–19 Rs2336384, rs873458, rs873457, and rs4846085 are located within intron 2, rs2878677 within intron 3, and rs2236057 within intron 11 of Mfn2. Genomic DNA was extracted from peripheral blood leukocytes using a genomic DNA kit (GENEray Biotechnology, Shanghai, China). Mfn2 gene polymorphisms were detected using the ligase detection reaction (LDR). Briefly, after extracting the DNA from the peripheral blood leukocytes, PCR amplification was performed using the following conditions: an initial denaturation of 5 minutes at 95°C, followed by 35 cycles of denaturation at 94°C for 20 s, annealing at 55°C for 20 s, and extension at 72°C for 40 s, with a final extension at 72°C for 10 minutes. For the LDR, the probe was added to each PCR reaction well, mixed, spun by centrifugation, and amplified for 30 cycles at 94°C for 20 s and 58°C for 90 s. Then, 1 µL of that product was added to 9 µL of highly deionized formamide, desaturated at 95°C for 3 minutes, plunged into an ice bath, and tested immediately.

Primer Premier 5.0 software (Premier Biosoft Intl., San Francisco, CA, USA) was used to design primers for amplification based on the Mfn2 Genbank reference sequence (NG_007945.1; Supplementary Table 1). Probes were designed using GENEray Biotechnology (Shanghai, China; Supplementary Table 2). Genotypes were evaluated using DNA sequencing on an ABI 3730 genetic analyzer (Applied Biosystems, Waltham, MA, USA) following the manufacturer’s instructions, and sequenced with GeneMarker V2.2.0 (SoftGenetics, LLC., State College, PA, USA).

Statistical analyses

Statistical analyses were performed using IBM SPSS Statistics software, version 26.0 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as the mean ± standard deviation (SD), skewed variables as the median (interquartile range), and categorical variables as percentage. Student’s t-tests, Mann–Whitney U tests, and chi-squared tests were used, respectively, to compare paired groups. Risk estimates for MAFLD with respect to the six Mfn2 SNPs for different genetic models (additive, recessive, dominant, and co-dominant models) were determined by binary logistic regression. Hardy–Weinberg equilibrium (HWE), linkage disequilibrium (LD), and haplotype blocks were assessed using Haploview software 4.2 (r² was set to 0.85) (http://www.broad.mit.edu/mpg/haploview/). A two-tailed P-value < 0.05 was considered statistically significant.

Results

Characteristics of the subjects

A total of 889 unrelated participants were enrolled in the study, including 466 MAFLD cases (208 men and 258 women) and 423 healthy controls (162 men and 261 women). A flow chart of the study protocol is shown in Figure 1. The clinical characteristics and laboratory data for all participants are shown in Table 1. There was adequate sex matching between MAFLD subjects and controls. The mean age of the MAFLD group was higher than that of controls (P < 0.001). The mean values of the following variables were significantly higher among the MAFLD patients compared with the controls: BMI, diastolic blood pressure (DBP), systolic blood pressure (SBP), WBC count, and levels of alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), and uric acid (UA) (P < 0.001; Table 1). The mean values for high-density lipoprotein cholesterol (HDL-C) levels were lower in the MAFLD group (P < 0.001). The mean plasma albumin concentrations were significantly lower among women and in the entire MAFLD cohort (P < 0.001), but not among male MAFLD patients.

Figure 1.

Flowchart showing the patient enrollment process in this study.

Table 1.

Demographic and biochemical characteristics of the healthy controls and metabolic dysfunction associated fatty liver disease (MAFLD) patients.

Variable	Total control group (n = 423)	Total MAFLD group (n = 466)	P-value	Male controls (n = 162)	Male MAFLD patients (n = 208)	P-value	Female controls (n = 261)	Female MAFLD patients (n = 258)	P-value
Age (years)	31.00 (27.00–35.00)	40.00 (32.00–52.00)	<0.001	32.00 (26.00–38.00)	37.00 (31.50–45.00)	<0.001	31.00 (27.00–34.00)	45.00 (33.00–55.00)	<0.001
BMI (kg/m²)	20.96 (19.81–22.04)	27.55 (26.03–29.41)	<0.001	21.76 (20.52–22.98)	28.72 (26.72–30.81)	<0.001	20.55 (19.53–21.48)	27.03 (25.56–28.58)	<0.001
DBP (mmHg)	70.00 (65.00–75.50)	83.00 (76.00–89.00)	<0.001	74.00 (70.00–79.00)	84.00 (79.00–90.00)	<0.001	69.00 (64.00–73.00)	83.00 (75.00–89.00)	<0.001
SBP (mmHg)	116.00 (109.00–124.00)	134.00 (125.00–144.00)	<0.001	122.00 (115.00–129.00)	135.00 (129.00–145.50)	<0.001	113.00 (107.00–119.00)	131.00 (121.00–143.00)	<0.001
WBC (10⁹/L)	5.74 (4.99–6.71)	6.87 (5.85–8.10)	<0.001	5.89 (5.19–6.79)	7.07 (6.04–8.32)	<0.001	5.64 (4.92–6.66)	6.68 (5.77–7.93)	<0.001
ALB (g/L)	48.51 ± 3.03	47.74 ± 3.19	<0.001	49.44 (47.41–51.32)	49.23 (47.29–50.74)	0.398	47.82 (46.21–49.87)	46.62 (44.82–48.70)	<0.001
ALT (U/L)	15.00 (11.00–19.00)	28.00 (19.00–44.00)	<0.001	17.50 (14.00–25.00)	37.50 (25.00–58.00)	<0.001	13.00 (10.00–17.00)	22.00 (16.00–35.00)	<0.001
AST (U/L)	17.00 (15.00–19.00)	21.00 (17.00–27.00)	<0.001	18.00 (15.00–21.00)	23.50 (20.00–30.50)	<0.001	16.00 (15.00–18.00)	19.00 (16.00–24.00)	<0.001
TC (mmol/L)	4.36 (3.91–4.67)	5.17 (4.63–5.80)	<0.001	4.45 (4.10–4.90)	5.25 (4.69–5.94)	<0.001	4.19 (3.85–4.60)	5.15 (4.59–5.75)	<0.001
TG (mmol/L)	0.81 (0.65–1.02)	1.78 (1.24–2.49)	<0.001	0.94 (0.77–1.20)	1.90 (1.42–2.96)	<0.001	0.74 (0.61–0.89)	1.67 (1.17–2.33)	<0.001
HDL-C (mmol/L)	1.46( 1.32–1.64)	1.26 (1.14–1.42)	<0.001	1.36 (1.21–1.53)	1.19 (1.09–1.32)	<0.001	1.55 ± 0.23	1.34 ± 0.23	<0.001
LDL-C (mmol/L)	2.39 (2.12–2.66)	3.20 (2.83–3.76)	<0.001	2.60 ± 0.46	3.25 ± 0.62	<0.001	2.26 (2.02–2.51)	3.23 (2.76–3.82)	<0.001
FPG (mmol/L)	5.07 (4.83–5.30)	5.60 (5.18–6.26)	<0.001	5.19 (4.92–5.41)	5.61 (5.25–6.35)	<0.001	5.00 (4.76–5.23)	5.59 (5.11–6.19)	<0.001
UA (μmol/L)	292.00 (249.00–345.22)	371.00 (307.57–435.00)	<0.001	353.00 (323.00–385.00)	431.00 (370.50–489.50)	<0.001	259.00 (229.00–293.00)	331.00 (286.00–385.00)	<0.001

Continuous variables are expressed as the mean ± standard deviation when normally distributed and as the median (interquartile range) when non-normally distributed. MAFLD, metabolic associated fatty liver disease; BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; WBC, white blood cell count; ALB, albumin; ALT, alanine transaminase; AST, aspartate transaminase; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; FPG, fasting plasma glucose; UA, uric acid.

Detection and distribution of SNPs

All six Mfn2 SNPs were successfully genotyped for all participants (Table 2). All SNPs showed genotype frequencies in accordance with HWE in the control group (Table 2). Chi-square analyses indicated significant differences in the distributions of the rs2336384, rs2878677, and rs2236057 genotypes in MAFLD patients compared with healthy controls (P < 0.05). For rs2878677, the C allele prevalence was significantly higher among MAFLD patients (P < 0.05), whereas no differences were found for the distributions of rs2336384 and rs2236057. Analysis by sex revealed a different genotype distribution for rs2878677 between female MAFLD patients and controls. No sex-based differences in the allele ratio was found.

Table 2.

Genotype distribution and allele frequency of the Mfn2 gene in healthy controls and metabolic dysfunction associated fatty liver disease (MAFLD) patients.

SNP	Genotype (frequency, %)			P-value	Allele (frequency, %)		P-value
rs2336384	GG	GT	TT		G	T
Total
Control	101 (23.9)	219 (51.8)	103 (24.3)	0.015	421 (49.8)	425 (50.2)	0.138
MAFLD	77 (16.5)	277 (59.4)	112 (24.0)	0.015	431 (46.2)	501 (53.8)	0.138
Male
Control	35 (21.6)	89 (54.9)	38 (23.5)	0.109	159 (49.1)	165 (50.9)	0.238
MAFLD	28 (13.5)	130 (62.5)	50 (24.0)	0.109	186 (44.7)	230 (55.3)	0.238
Female
Control	66 (25.3)	130 (49.8)	65 (24.9)	0.164	262 (50.2)	260 (49.8)	0.382
MAFLD	49 (19.0)	147 (57.0)	62 (24.0)	0.164	245 (47.5)	271 (52.5)	0.382
rs873458	AA	AG	GG		A	G
Total
Control	51 (12.1)	202 (47.8)	170 (40.2)	0.506	304 (35.9)	542 (64.1)	0.397
MAFLD	57 (12.2)	239 (51.3)	170 (36.5)	0.506	353 (37.9)	579 (62.1)	0.397
Male
Control	22 (13.6)	75 (46.3)	65 (40.1)	0.236	119 (36.7)	205 (63.3)	0.202
MAFLD	30 (14.4)	112 (53.9)	66 (31.7)	0.236	172 (41.3)	244 (58.7)	0.202
Female
Control	29 (11.1)	127 (48.7)	105 (40.2)	0.971	185 (35.4)	337 (64.6)	0.903
MAFLD	27 (10.5)	127 (49.2)	104 (40.3)	0.971	181 (35.1)	335 (64.9)	0.903
rs873457	CC	CG	GG		C	G
Total
Control	103 (24.3)	216 (51.1)	104 (24.6)	0.053	422 (49.9)	424 (50.1)	0.114
MAFLD	83 (17.8)	264 (56.7)	119 (25.5)	0.053	430 (46.1)	502 (53.9)	0.114
Male
Control	36 (22.2)	88 (54.3)	38 (23.5)	0.296	160 (49.4)	164 (50.6)	0.286
MAFLD	33 (15.9)	123 (59.1)	52 (25.0)	0.296	189 (45.4)	227 (54.6)	0.286
Female
Control	67 (25.7)	128 (49.0)	66 (25.3)	0.213	262 (50.2)	260 (49.8)	0.261
MAFLD	50 (19.4)	141 (54.7)	67 (26.0)	0.213	241 (46.7)	275 (53.3)	0.261
rs4846085	TT	CT	CC		T	C
Total
Control	101 (23.9)	219 (51.8)	103 (24.3)	0.111	421 (49.8)	425 (50.2)	0.178
MAFLD	85 (18.2)	264 (56.7)	117 (25.1)	0.111	434 (46.6)	498 (53.4)	0.178
Male
Control	35 (21.6)	89 (54.9)	38 (23.5)	0.436	159 (49.1)	165 (50.9)	0.358
MAFLD	34 (16.3)	122 (58.7)	52 (25.0)	0.436	190 (45.7)	226 (54.3)	0.358
Female
Control	66 (25.3)	130 (49.8)	65 (24.9)	0.296	262 (50.2)	260 (49.8)	0.349
MAFLD	51 (19.8)	142 (55.0)	65 (25.2)	0.296	244 (47.3)	272 (52.7)	0.349
rs2878677	TT	CT	CC		T	C
Total
Control	100 (23.6)	206 (48.7)	117 (27.7)	0.006	406 (48.0)	440 (52.0)	0.028
MAFLD	71 (15.2)	257 (55.2)	138 (29.6)	0.006	399 (42.8)	533 (57.2)	0.028
Male
Control	34 (21.1)	85 (52.5)	43 (26.5)	0.232	153 (47.2)	171 (52.8)	0.143
MAFLD	30 (14.4)	114 (54.8)	64 (30.8)	0.232	174 (41.8)	242 (58.2)	0.143
Female
Control	66 (25.3)	121 (46.4)	74 (28.3)	0.022	253 (48.5)	269 (51.5)	0.116
MAFLD	41 (15.9)	143 (55.4)	74 (28.7)	0.022	225 (43.6)	291 (56.4)	0.116
rs2236057	AA	AG	GG		A	G
Total
Control	89 (21.0)	210 (49.7)	124 (29.3)	0.036	388 (45.9)	458 (54.1)	0.128
MAFLD	68 (14.6)	258 (55.4)	140 (30.0)	0.036	394 (42.3)	538 (57.7)	0.128
Male
Control	30 (18.5)	87 (53.7)	45 (27.8)	0.205	147 (45.4)	177 (54.6)	0.154
MAFLD	25 (12.0)	117 (56.3)	66 (31.7)	0.205	167 (40.1)	249 (59.9)	0.154
Female
Control	59 (22.6)	123 (47.1)	79 (30.3)	0.143	241 (46.2)	281 (53.8)	0.481
MAFLD	43 (16.7)	141 (54.7)	74 (28.7)	0.143	227 (44.0)	289 (56.0)	0.481

SNP, single nucleotide polymorphism.

Correlation analyses

Different genetic models, additive, recessive, dominant, and co-dominant, were assessed by logistic regression analyses. The rs2336384 polymorphism was inversely correlated with MAFLD when analyzed by both the recessive genetic model (GG vs. GT + TT: P = 0.006; odds ratio (OR) = 1.585; 95% confidence interval (CI) = 1.138–2.207) and co-dominant genetic model (GG + TT vs. GT: P = 0.022; OR = 1.365; 95% CI = 1.047–1.781), suggesting that having the G allele of rs2336384 carries a higher risk of MAFLD (Table 3). Furthermore, analysis by the additive genetic model (TT vs. CT vs. CC: P = 0.025; OR = 1.247; 95% CI = 1.028–1.513) and the recessive genetic model (TT vs. CT + CC: P = 0.002; OR = 1.722; 95% CI = 1.229–2.415) demonstrated an increased risk of MAFLD for subjects carrying the TT genotype of the rs2878677 polymorphism. SNPs of rs873457, rs4846085, and rs2236057 were inversely correlated with MAFLD in recessive genetic models (rs873457: CC vs. CG + GG: P = 0.017; OR = 1.485; 95% CI = 1.073–2.056; rs4846085: TT vs. CT +CC: P = 0.048; OR = 1.388; 95% CI = 1.003–1.921; rs2236057: AA vs. AG + GG: P = 0.012; OR = 1.560; 95% CI = 1.102–2.208). No significant association between the rs873458 polymorphism and MAFLD risk was found (Table 3). Sex-based subgroup analyses revealed a different finding in recessive modelling of rs2336384 in men (GG vs. GT + TT: P = 0.040; OR = 1.772; 95% CI = 1.026–3.060) and recessive and co-dominant modelling of rs2878677 in women (TT vs. CT + CC: P = 0.009; OR = 1.791; 95% CI = 1.159–2.768; TT + CC vs. CT: P = 0.039; OR = 1.439; 95% CI = 1.018–2.033; Table 3).

Table 3.

Association of Mfn2 gene polymorphisms with metabolic dysfunction associated fatty liver disease (MAFLD) interpreted by different genetic models.

SNP	Model	Genotype	Overall		Male		Female
SNP	Model	Genotype	OR (95%CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
rs2336384
	Additive	GG vs. GT vs. TT	1.174 (0.962–1.432)	0.115	1.242 (0.898–1.719)	0.191	1.124 (0.873–1.446)	0.366
	Recessive	GG vs. GT + TT	1.585 (1.138–2.207)	0.006	1.772 (1.026–3.060)	0.040	1.444 (0.950–2.193)	0.085
	Dominant	GG + GT vs. TT	0.983 (0.723–1.337)	0.913	1.033 (0.637–1.674)	0.896	0.954 (0.639–1.423)	0.817
	Co-dominant	GG + TT vs. GT	1.365 (1.047–1.781)	0.022	1.367 (0.900–2.076)	0.142	1.335 (0.944–1.886)	0.102
rs873458
	Additive	AA vs. AG vs. GG	0.910 (0.745–1.111)	0.353	0.802 (0.589–1.092)	0.162	1.017 (0.781–1.325)	0.899
	Recessive	AA vs. AG + GG	0.984 (0.657–1.472)	0.936	0.932 (0.515–1.687)	0.817	1.069 (0.614–1.863)	0.813
	Dominant	AA + AG vs. GG	0.855 (0.652–1.121)	0.256	0.694 (0.452–1.065)	0.095	1.003 (0.706–1.425)	0.985
	Co-dominant	AA + GG vs. AG	1.152 (0.885–1.499)	0.293	1.353 (0.896–2.043)	0.150	1.023 (0.725–1.443)	0.897
rs873457
	Additive	CC vs. CG vs. GG	1.178 (0.969–1.432)	0.100	1.204 (0.878–1.651)	0.249	1.156 (0.902–1.483)	0.252
	Recessive	CC vs. CG + GG	1.485 (1.073–2.056)	0.017	1.515 (0.896–2.561)	0.121	1.437 (0.948–2.176)	0.087
	Dominant	CC + CG vs. GG	1.052 (0.776–1.425)	0.744	1.088 (0.673–1.758)	0.731	1.036 (0.699–1.537)	0.859
	Co-dominant	CC + GG vs. CG	1.252 (0.961–1.632)	0.095	1.217 (0.804–1.842)	0.354	1.252 (0.887–1.768)	0.201
rs4846085
	Additive	TT vs. CT vs. CC	1.151 (0.947–1.400)	0.159	1.173 (0.856–1.608)	0.321	1.130 (0.880–1.451)	0.337
	Recessive	TT vs. CT + CC	1.388 (1.003–1.921)	0.048	1.359 (0.802–2.303)	0.254	1.374 (0.908–2.079)	0.133
	Dominant	TT + CT vs.CC	1.042 (0.768–1.413)	0.794	1.088 (0.673–1.758)	0.731	1.016 (0.683–1.511)	0.939
	Co-dominant	TT + CC vs. CT	1.217 (0.935–1.586)	0.145	1.164 (0.769–1.761)	0.474	1.234 (0.874–1.742)	0.233
rs2878677
	Additive	TT vs. CT vs. CC	1.247 (1.028–1.513)	0.025	1.273 (0.935–1.733)	0.125	1.223 (0.954–1.568)	0.112
	Recessive	TT vs. CT + CC	1.722 (1.229–2.415)	0.002	1.576 (0.918–2.707)	0.099	1.791 (1.159–2.768)	0.009
	Dominant	TT + CT vs. CC	1.100 (0.822–1.473)	0.520	1.230 (0.779–1.941)	0.374	1.016 (0.694–1.488)	0.934
	Co-dominant	TT + CC vs. CT	1.295 (0.995–1.687)	0.055	1.099 (0.728–1.659)	0.654	1.439 (1.018–2.033)	0.039
rs2236057
	Additive	AA vs. AG vs. GG	1.170 (0.963–1.421)	0.115	1.279 (0.932–1.756)	0.127	1.095 (0.854–1.403)	0.475
	Recessive	AA vs. AG + GG	1.560 (1.102–2.208)	0.012	1.664 (0.935–2.960)	0.083	1.460 (0.943–2.262)	0.090
	Dominant	AA + AG vs. GG	1.036 (0.776–1.381)	0.812	1.208 (0.770–1.897)	0.411	0.927 (0.635–1.351)	0.692
	Co-dominant	AA + GG vs. AG	1.258 (0.966–1.638)	0.088	1.108 (0.734–1.675)	0.625	1.352 (0.957–1.909)	0.087

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Haplotype analysis

Calculations of r² were made for all SNPs under investigation. The Haploview program showed that all six Mfn2 polymorphisms were located in a strong LD block and were interlinked with each other (Figure 2). The full haplotype analyses of all six Mfn2 polymorphisms in MAFLD patients and controls are presented in Table 4. The haplotype, GGCTTA (rs2336384 - rs873457 - rs873458 - rs4846085 - rs2878677 - rs2236057), was lower among MAFLD patients (39.7%) than in the controls (45.2%; P = 0.029). No significant association was found between other haplotypes and MAFLD risk.

Figure 2.

Linkage disequilibrium (LD) block defined by the Haploview program using the solid spine of LD method. (a) LD of D′ and (b) LD of r2.

Table 4.

Haplotype analyses of the Mfn2 polymorphisms in healthy controls and metabolic dysfunction associated fatty liver disease (MAFLD) patients

Haplotype						Frequency		χ²	P-value	Male		χ²	P-value	Female		χ²	P-value
M1	M2	M3	M4	M5	M6	Control	MAFLD	χ²	P-value	Control	MAFLD	χ²	P-value	Control	MAFLD	χ²	P-value
G	G	C	T	T	A	0.452	0.397	4.796	0.029	0.451	0.399	3.350	0.067	0.453	0.410	1.966	0.161
T	A	G	C	C	G	0.353	0.359	0.170	0.680	0.361	0.384	1.108	0.293	0.348	0.334	0.204	0.651
T	G	G	C	C	G	0.145	0.158	0.628	0.428	0.142	0.130	0.228	0.633	0.146	0.174	2.054	0.152
G	G	C	T	T	G	0.023	0.020	0.048	0.826	0.022	0.029	0.855	0.355	0.023	0.019	0.334	0.564
G	G	C	T	C	G	0.019	0.024	0.591	0.442	0.019	0.022	0.002	0.961	0.019	0.016	0.007	0.935

M1: rs2336384, M2: rs873458, M3: rs873457, M4: 4846085, M5: 2878677, M6: 2236057.

Discussion

In this study, we identified and genotyped six SNPs of the Mfn2 gene using Haploview software and SPSS statistical analysis to assess the risk factors for MAFLD by binary logistic regression analyses. Our findings show that Mfn2 polymorphisms rs2336384, rs2878677, and rs2236057 are strongly correlated with MAFLD risk in the Han Chinese population. Moreover, the haplotype, GGCTTA, appears to be a protective factor for MAFLD. Sex-specific subgroup analysis demonstrated the relationship between the rs2236384 and rs2878677 polymorphisms and risk of MAFLD in men and women, respectively. To our knowledge, the current study is the first to focus on Mfn2 gene polymorphisms and MAFLD in the Chinese population before or because MAFLD has been newly defined.

Several previous studies have investigated associations between Mfn2 gene polymorphisms and diseases related to metabolic dysfunction. In 2011, Wang et al.¹⁶ and Li et al.¹⁷ found that Mfn2 gene polymorphisms (rs873457, rs2336384, rs147486, rs4846085, rs2236055¹⁶ and rs2336384, rs2295281, rs17037564, rs2236057, rs2236058, rs3766741,¹⁷ respectively) were associated with the sub-groups of MAFLD patients who have essential hypertension (EH) in Chinese subjects. In addition, Liu et al.¹⁵ established a link between Mfn2 polymorphisms (rs873458, rs2878677, rs2236058, rs3766742, and rs3766741) and type 2 diabetes in Han Chinese people. In combination, these findings suggest that Mfn2 gene polymorphisms play a major role in the occurrence and development of metabolism-related diseases. However, the studies listed above do not demonstrate a direct association between SNPs and MAFLD. To bridge this gap in knowledge, we selected six representative SNPs in the Mfn2 gene and explored the links between them and MAFLD in patients from a northern Han Chinese population. It was considered that the population being studied shows consistent characteristics of geographical stability, environmental exposure, and genetic homogeneity.^20,21 It is vital to exclude the influence of such factors when investigating the genetics of a metabolic disorder, such as MAFLD, and our findings were consistent with those of previous studies on metabolic dysfunction.^15–18,22 Our current findings suggest that Mfn2 gene polymorphisms can be correlated with the risk of MAFLD.

Subgroup analysis revealed a degree of sex-specificity regarding the impact of Mfn2 polymorphisms. We found an association between rs2336384 and MAFLD risk in men and a similar association for rs2878677 in women. There are several possible reasons for these sex-specific differences: 1) Differing genetic structure between women and men²³ may influence MAFLD susceptibility genes; 2) Regulation of Mfn2 gene expression may be different in men compared with women because of varying rates of smoking, drinking, mental stress, low estrogen levels, and other reasons;²⁴ 3) Some receptors relevant to the current study may have sex-specific activities, such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), peroxisome proliferator-activated receptor alpha (PPARα), farnesoid X receptor (FXR), and liver X receptor (LXR), all of which may contribute to the steatosis that characterizes MAFLD.^24,25 Any or all of these risk factors could be hypothesized to interact with the Mfn2 gene variation and influence the regulation of fatty acid metabolism.

While a single SNP has a vanishingly small influence on phenotype, multiple SNPs, especially when closely linked, may have a large collective impact. Hence, haplotype analysis can contribute more to genetic studies of complex diseases, such as MAFLD, than studies of single SNPs. The six SNPs examined here were located in one block and displayed strong LD with each other. Haplotype analysis indicated an association of GGCTTA (rs2336384 - rs873458 - rs873457 - rs4846085 - rs2878677 - rs2236057) with a decreased risk of MAFLD. We believe that the current report is the first to identify these six Mfn2 polymorphisms (rs2336384, rs873458, rs873457, rs4846085, rs2878677, and rs2236057) as a protective haplotype block for MAFLD. Moreover, we found that the haplotypes, TAGCCG, TGGCCG, and GGCTCG, are more likely to be associated with an increased risk of MAFLD, albeit there was no difference between the MAFLD and control groups.

The complex and multifactorial development of MAFLD is characterized by pathophysiological mechanisms, including disordered lipid metabolism, oxidative stress, and IR. Mfn2 has a prominent regulatory role in this process^13,26 and shows reduced activity in obesity and type 2 diabetes.^27,28 Indeed, Gan et al. demonstrated an impact of Mfn2 protein deficiency on disordered mitochondrial architecture, decreased oxidative capacity, and glucose-derived pyruvate in mice. These phenotypes could be reversed by overexpressing Mfn2. The insulin signaling pathway appeared to be the target of these effects.^11,26 Insulin may block the Mfn2-dependent mitogen-activated protein kinase kinase 1 (MEK) cascade and activate the phosphoinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, which stimulates mitochondrial activity and promotes mitochondrial fusion.²⁹ Conversely, downregulation of Mfn2 can decrease mitochondrial β-oxidation of fatty acids, enhancing TG accumulation and impairing the respiratory chain. This ultimately leads to ROS generation. Lower Mfn2 activity can also result in activation of the JNK and p38MAPK pathways and inhibition of the Akt pathway. The cumulative effect of these alterations can promote IR in both skeletal muscle and liver.^30,31 Ablation of Mfn2 in hypothalamic proopiomelanocortin neurons has also been shown to lead to ER stress, leptin resistance, and consequentially hyperphagia, reduced energy expenditure, and obesity. All of these effects could be reversed by relieving hypothalamic ER stress.³² Furthermore, lipotoxin damage induced by saturated lipids reduces Mfn2 expression, stimulating the ER stress response and IR in hypothalamic-derived cells.³³ Taken together, these findings confirm the role for Mfn2 and its impact on ER stress in local and systemic energy balance.

To summarize, fatty acids and glucose-derived pyruvate are metabolized in mitochondria through the tricarboxylic acid cycle. An increase in glucose metabolism, along with reduced fatty acid oxidation, stimulates ROS production and causes decreased Mfn2 expression. Downstream consequences include activation of mitochondrial fission, suppression of mitochondrial calcium release, impaired mitochondrial metabolism, and reduced mitochondrial membrane potential. The resulting oxidative stress and ER stress promote mitochondrial apoptosis, thereby enhancing the metabolic disorders that lead to MAFLD.^34–38 The current genetic analysis, in combination with evidence from previous studies, supports the conclusion that Mfn2 influences the occurrence of MAFLD and is a potential therapeutic target for this disorder.

Introns are crucial for the regulation of eukaryotic gene expression by interacting with enhancers or alternative promoters of transcriptional regulatory elements, or through the intron-mediated enhancement that increases the processivity of the transcription machinery at the elongation stage.³⁹ There are many reports of genes with complete promoters that fail to be expressed without introns.⁴⁰ The current study identified three positive SNPs in Mfn2 gene introns that were significantly associated with MAFLD. It is likely that these polymorphisms have an impact on the transcriptional regulation of Mfn2. Further mechanistic studies should be performed in cultured cells using transfection to introduce different polymorphisms of the Mfn2 introns to assess their impact on gene expression.

This study has some limitations. The subjects were exclusively of northern Han origin, and it is unclear how our findings may apply to other populations. Only relatively severe cases of MAFLD were enrolled and matched with control participants who were not overweight or obese. Some selection bias may have been introduced because the study participants were more health-conscious than the general population. Moreover, there was some deficiency in data collection, such as detailed alcohol consumption. Any correlations between Mfn2 gene polymorphisms and MAFLD biomarkers were not examined. We intend to focus on this aspect in future work to identify any potential associations.

Conclusions

The current study revealed that SNPs of the Mfn2 gene (rs2336384, rs2878677, and rs2236057) and the haplotype, GGCTTA, were strongly associated with MAFLD in a northern Han Chinese population. Sex-based analyses revealed that rs2336384 correlated with MAFLD in men and rs2878677 correlated with MAFLD in women. This study contributes to our understanding of the association between Mfn2 and MAFLD. Additional work is necessary to extend these findings to larger sample sizes and different populations. Future research may focus on the specific molecular mechanisms of these polymorphisms in MAFLD.

Supplemental Material

sj-pdf-1-imr-10.1177_03000605231187953 - Supplemental material for Mitofusin-2 gene polymorphisms and metabolic dysfunction associated fatty liver disease: a case-control study in a Chinese population

Supplemental material, sj-pdf-1-imr-10.1177_03000605231187953 for Mitofusin-2 gene polymorphisms and metabolic dysfunction associated fatty liver disease: a case-control study in a Chinese population by Xiwei Yuan, Mengmeng Hou, Yiqi Wang, Siyu Zhang, Lu Li, Yingjun Mi, Huijuan Du, Songhao Yu and Yuemin Nan in Journal of International Medical Research

Footnotes

Acknowledgements

The authors would like to express their gratitude to EditSprings () for the expert linguistic services provided.

Author contributions

YN contributed to the study design and revised the manuscript draft. XY performed statistical analysis and wrote the manuscript draft. MH, YW, and SY collected the data and performed the study. SZ and LL verified the statistical analysis. YM and HD provided technical support. All authors have read and approved the final manuscript.

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declaration of conflicting interests

The authors declare that there is no conflict of interest.

Funding

The study was supported by National Natural Science Foundation of China (Grant No. 81970504), Natural Science Foundation of Hebei Province (Grant No. H2018206326), and Key Research and Development Program of Hebei Province (Grant No. 19277779D).

ORCID iD

Yuemin Nan

References

Lim

Kim

Targher

. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021; 32: 500–514. https://doi.org/10.1016/j.tem.2021.04.008.

Eslam

Newsome

Sarin

, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73: 202–209. https://doi.org/10.1016/j.jhep.2020.03.039.

Younossi

Anstee

Marietti

, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11–20. https://doi.org/10.1038/nrgastro.2017.109.

Eslam

Sanyal

George

, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology 2020; 158: 1999–2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

Inoue

Qin

Poti

, et al. Epidemiology of Obesity in Adults: Latest Trends. Curr Obes Rep 2018; 7: 276–288. https://doi.org/10.1007/s13679-018-0317-8.

Friedman

Neuschwander-Tetri

Rinella

, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908–922. https://doi.org/10.1038/s41591-018-0104-9.

Eslam

George

Genetic Insights for Drug Development in NAFLD. Trends Pharmacol Sci 2019; 40: 506–516. https://doi.org/10.1016/j.tips.2019.05.002.

Eslam

Valenti

Romeo

Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol 2018; 68: 268–279. https://doi.org/10.1016/j.jhep.2017.09.003.

Auger

Alhasawi

Contavadoo

, et al. Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders. Front Cell Dev Biol 2015; 3: 40. https://doi.org/10.3389/fcell.2015.00040.

10.

Kai

Yang

Wang

, et al. Oroxylin a promotes PGC-1α/Mfn2 signaling to attenuate hepatocyte pyroptosis via blocking mitochondrial ROS in alcoholic liver disease. Free Radic Biol Med 2020; 153: 89–102.

11.

Gan

Wang

Chen

, et al. Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats. World J Gastroenterol 2013; 19: 1572–1581. https://doi.org/10.3748/wjg.v19.i10.1572.

12.

Sebastián

Sorianello

Segalés

, et al. Mfn2 deficiency links age‐related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway. Embo J 2016; 35: 1677–1693. https://doi.org/10.15252/embj.201593084.

13.

Chen

Guo

, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol 2004; 6: 872–883. https://doi.org/10.1038/ncb1161.

14.

Guo

Chen

Gao

, et al. Overexpression of Mitofusin 2 inhibited oxidized low-density lipoprotein induced vascular smooth muscle cell proliferation and reduced atherosclerotic lesion formation in rabbit. Biochem Biophys Res Commun 2007; 363: 411–417. https://doi.org/10.1016/j.bbrc.2007.08.191.

15.

Zhu

, et al. Association of Polymorphisms in Mitofusin-2 Gene with Type 2 Diabetes in Han Chinese. J Biomed Biotechnol 2012; 2012: 205752. https://doi.org/10.1155/2012/205752.

16.

Wang

Liu

, et al. HSG/Mfn2 Gene Polymorphism and Essential Hypertension: a Case-Control Association Study in Chinese. J Atheroscler Thromb 2011; 18: 24–31. https://doi.org/10.5551/jat.5611.

17.

Zhang

, et al. The Association of Mitofusion-2 Gene Polymorphisms with Susceptibility of Essential Hypertension in Northern Han Chinese Population. Int J Med Sci 2016; 13: 39–47. https://doi.org/10.7150/ijms.13012.

18.

Han

Liu

Zhou

, et al. Single Nucleotide Polymorphisms (SNPs) Genotyping Reveals that Mfn2 Polymorphisms are Associated with Thoracic Aortic Dissection in Han Chinese Population. Med Sci Monit 2019; 25: 2419–2428. https://doi.org/10.12659/MSM.915272.

19.

Von Elm

Altman

Egger

, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577.

20.

Yin

, et al. Genomic Dissection of Population Substructure of Han Chinese and Its Implication in Association Studies. Am J Hum Genet 2009; 85: 762–774. https://doi.org/10.1016/j.ajhg.2009.10.015.

21.

Wen

, et al. Genetic evidence supports demic diffusion of Han culture. Nature 2004; 431: 302–305.

22.

Wei

Tian

Zhao

, et al. Association between MFN2 gene polymorphisms and the risk and prognosis of acute liver failure: a case-control study in a Chinese population. Braz J Med Biol Res 2017; 50: e5758. https://doi.org/10.1590/1414-431x20175758.

23.

Alzheimer’s Disease Neuroimaging Initiative (ADNI), The Alzheimer Disease Genetics Consortium (ADGC), Deming

Dumitrescu

Barnes

, et al. Sex-specific genetic predictors of Alzheimer’s disease biomarkers. Acta Neuropathol 2018; 136: 857–872. https://doi.org/10.1007/s00401-018-1881-4.

24.

Cvitanović Tomaš

Urlep

Moškon

, et al. LiverSex Computational Model: Sexual Aspects in Hepatic Metabolism and Abnormalities. Front Physiol 2018; 9: 360. https://doi.org/10.3389/fphys.2018.00360.

25.

Soriano

Liesa

Bach

, et al. Evidence for a Mitochondrial Regulatory Pathway Defined by Peroxisome Proliferator-Activated Receptor- Coactivator-1, Estrogen-Related Receptor-, and Mitofusin 2. Diabetes 2006; 55: 1783–1791. https://doi.org/10.2337/db05-0509.

26.

Sebastian

Hernandez-Alvarez

Segales

, et al. Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci U S A 2012; 109: 5523–5528. https://doi.org/10.1073/pnas.1108220109.

27.

Bach

Naon

Pich

, et al. Expression of Mfn2, the Charcot-Marie-Tooth Neuropathy Type 2A Gene, in Human Skeletal Muscle: Effects of Type 2 Diabetes, Obesity, Weight Loss, and the Regulatory Role of Tumor Necrosis Factor and Interleukin-6. Diabetes 2005; 54: 2685–2693. https://doi.org/10.2337/diabetes.54.9.2685.

28.

Bach

Pich

Soriano

, et al. Mitofusin-2 Determines Mitochondrial Network Architecture and Mitochondrial Metabolism. J Biol Chem 2003; 278: 17190–17197. https://doi.org/10.1074/jbc.M212754200.

29.

Pawlikowska

Gajkowska

Orzechowski

Mitofusin 2 (Mfn2): a key player in insulin-dependent myogenesis in vitro. Cell Tissue Res 2007; 327: 571–581. https://doi.org/10.1007/s00441-006-0320-3.

30.

Filadi

Pendin

Pizzo

Mitofusin 2: from functions to disease. Cell Death Dis 2018; 9: 330. https://doi.org/10.1038/s41419-017-0023-6.

31.

Gao

Lei

, et al. NEFA‐induced ROS impaired insulin signalling through the JNK and p38MAPK pathways in non‐alcoholic steatohepatitis. J Cell Mol Med 2018; 22: 3408–3422. https://doi.org/10.1111/jcmm.13617.

32.

Schneeberger

Dietrich

Sebastián

, et al. Mitofusin 2 in POMC Neurons Connects ER Stress with Leptin Resistance and Energy Imbalance. Cell 2013; 155: 172–187.

33.

Ozcan

Cao

Yilmaz

, et al. Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes. Science 2004; 306: 457–461.

34.

Zhou

Wang

Zhu

, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 2018; 15: 335–346. https://doi.org/10.1016/j.redox.2017.12.019.

35.

Capasso

Volek

, et al. BMP10-mediated ALK1 signaling is continuously required for vascular development and maintenance. Angiogenesis 2020; 23: 203–220. https://doi.org/10.1007/s10456-019-09701-0.

36.

Klinge

CM.

Estrogenic control of mitochondrial function. Redox Biol 2020; 31: 101435. https://doi.org/10.1016/j.redox.2020.101435.

37.

Lubos

Van der Gaag

Gerçek

, et al. Inflammation shapes pathogenesis of murine arrhythmogenic cardiomyopathy. Basic Res Cardiol 2020; 115: 42. https://doi.org/10.1007/s00395-020-0803-5.

38.

Wang

Toan

Zhou

New insights into the role of mitochondria in cardiac microvascular ischemia/reperfusion injury. Angiogenesis 2020; 23: 299–314. https://doi.org/10.1007/s10456-020-09720-2.

39.

Barrett

Fletcher

Wilton

SD.

Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 2012; 69: 3613–3634. https://doi.org/10.1007/s00018-012-0990-9.

40.

Rose

AB.

Intron-mediated regulation of gene expression. Curr Top Microbiol Immunol 2008; 326: 277–290. https://doi.org/10.1007/978-3-540-76776-3_15.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.13 MB